Abstract 118P
Background
The MET14 skipping mutation, prevalent in various tumors, notably in non-small cell lung cancer (NSCLC), is strongly associated with specific therapeutic targets. Our study aimed to detect MET14 skipping in pan-solid tumor samples using DNA and RNA next-generation sequencing NGS, evaluating assay sensitivity and specificity and mutation distribution across tumor types and populations.
Methods
8,049 samples were tested for MET14 skipping by DNA and RNA-based NGS in amplicon library constructs (ALC), while 7,676 samples were tested by DNA-based NGS in capture library constructs (CLC), with the analysis focusing on clinically significant mutations.
Results
In patients undergoing concurrent DNA/RNA-based NGS (ALC), 1.64% (132/8049) were positive, with lung cancer (LC) showing the highest rate at 2.12% (119/5618), followed by gastrointestinal tumors at 0.11% (3/2681). Lung sarcomatoid carcinoma had the highest MET14 skipping rate (13.6%; 3/22) among LC subtypes. The detection rates of patients with synchronized testing who tested positive by RNA or DNA-based NGS were 1.46% (123/8409) and 0.43% (36/8409), respectively. The detection rate of DNA-based NGS(CLC) was 0.55% (42/7676). Among simultaneously tested patients, 1.20% (96) of the 8,013 DNA-negative cases showed positive results on RNA testing, possibly due to probe design limitations at the Y1003 locus on the DNA level. Conversely, 9 of 36 DNA-positive cases were RNA-negative, indicating possible false-positive and false-negative problems with DNA detection. DNA NGS-based analysis showed that the splice donor site (SD) had the highest mutation rate at 28.3%. In addition, there was no significant difference in the detection rate of MET14 skipping between different tumor cell contents, sample types (e.g., pleural fluid vs. other tissues), and primary vs. metastatic foci (p>0.05). MET14 skipping was more frequent in patients aged 60 years and older (p<0.05), while there was no significant correlation between gender and detection rate.
Conclusions
RNA-based NGS is more accurate in detecting MET14 skipping mutations, and can directly recognize exons lost after transcription, independent of intronic variants, which effectively improves the accuracy of detection.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
102P - Dynamic profiling of ctDNA in HER2-alterated advanced NSCLC treated with pyrotinib and apatinib: Exploratory biomarker analysis from a phase II trial
Presenter: Yucheng Dong
Session: Poster session 08
103P - Epigenetic regulated genes enhanced fragmentomics-based model for early-stage lung cancer detection
Presenter: Yadong Wang
Session: Poster session 08
104P - The development of a classifier of somatic copy number alteration burden in liquid biopsy with potential clinical impact in advanced non-small cell lung cancer (NSCLC)
Presenter: Laura Bonanno
Session: Poster session 08
105P - Plasma ctDNA dynamics as clinical response biomarker for NSCLC: A systematic review and meta-analysis
Presenter: Luís Leite
Session: Poster session 08
106P - Longitudinal molecular characterization in plasma of EGFR mutant non-small cell lung cancer (NSCLC) experiencing early progression (EPD) on first-line osimertinib (Osi)
Presenter: Laura Bonanno
Session: Poster session 08
107P - Germline pathogenic variants identified in tissue- and blood-based whole exome sequencing in advanced solid tumors
Presenter: Takeshi Kuwata
Session: Poster session 08
108P - Assessing molecular characteristics in a large cohort of anal squamous cell carcinoma patients
Presenter: Cristina Smolenschi
Session: Poster session 08
109P - Development and validation of a digital PCR assay for detection and monitoring of universally methylated circulating tumor DNA in patients with high-grade sarcoma
Presenter: Elisabeth Ashton
Session: Poster session 08
110P - 13-plex non-invasive genotyping in HPV related cancers in the MOSCATO trial
Presenter: Elise Rupp
Session: Poster session 08
111P - Leveraging circulating tumor DNA sequencing for first-line cancer treatment: Insights from two prospective precision medicine studies
Presenter: Veronique Debien
Session: Poster session 08